These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 22494968)
1. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Tiaka EK; Papanas N; Manolakis AC; Georgiadis GS Perspect Vasc Surg Endovasc Ther; 2012 Mar; 24(1):37-44. PubMed ID: 22494968 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers. Dumantepe M; Fazliogullari O; Seren M; Uyar I; Basar F Growth Factors; 2015 Apr; 33(2):128-32. PubMed ID: 25856197 [TBL] [Abstract][Full Text] [Related]
3. Topical Recombinant Human Epidermal Growth Factor for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Clinical Trials. Yang Q; Zhang Y; Yin H; Lu Y Ann Vasc Surg; 2020 Jan; 62():442-451. PubMed ID: 31394225 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. Mohan VK Diabetes Res Clin Pract; 2007 Dec; 78(3):405-11. PubMed ID: 17655964 [TBL] [Abstract][Full Text] [Related]
5. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Hong JP; Jung HD; Kim YW Ann Plast Surg; 2006 Apr; 56(4):394-8; discussion 399-400. PubMed ID: 16557070 [TBL] [Abstract][Full Text] [Related]
7. [Clinical study of various growth factors on the improvement of impaired healing ulcers in patients with diabetic disease]. Feng J; Du WH; Wang J Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 1999 Sep; 13(5):273-7. PubMed ID: 12080817 [TBL] [Abstract][Full Text] [Related]
8. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Generini S; Tuveri MA; Matucci Cerinic M; Mastinu F; Manni L; Aloe L Exp Clin Endocrinol Diabetes; 2004 Oct; 112(9):542-4. PubMed ID: 15505764 [TBL] [Abstract][Full Text] [Related]
9. [Bio-inductive effects of inorganic elements on skin wound healing]. Zhou LS; Liao ZJ; Zhang Q; Luo M; Lu G; Zhang W Zhonghua Shao Shang Za Zhi; 2005 Oct; 21(5):363-6. PubMed ID: 16383040 [TBL] [Abstract][Full Text] [Related]
10. The Long-Term Outcomes Following the Application of Intralesional Epidermal Growth Factor in Patients With Diabetic Foot Ulcers. Kahraman M; Misir A; Kizkapan TB; Ozcamdalli M; Uzun E; Mutlu M J Foot Ankle Surg; 2019 Mar; 58(2):282-287. PubMed ID: 30612874 [TBL] [Abstract][Full Text] [Related]
11. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. Yera-Alos IB; Alonso-Carbonell L; Valenzuela-Silva CM; Tuero-Iglesias AD; Moreira-Martínez M; Marrero-Rodríguez I; López-Mola E; López-Saura PA BMC Pharmacol Toxicol; 2013 Sep; 14():44. PubMed ID: 24004460 [TBL] [Abstract][Full Text] [Related]
12. Intralesional and perilesional application of an epidermal growth factor (Heberprot-P®) in diabetic foot ulcers. Part one. Montequin JF; Bonachea LS; Acosta JB; Peres CV; Gutierres WS; Duarte GA Angiol Sosud Khir; 2018; 24(4):33-42. PubMed ID: 30531767 [TBL] [Abstract][Full Text] [Related]
13. Heberprot-P: a novel product for treating advanced diabetic foot ulcer. Berlanga J; Fernández JI; López E; López PA; del Río A; Valenzuela C; Baldomero J; Muzio V; Raíces M; Silva R; Acevedo BE; Herrera L MEDICC Rev; 2013 Jan; 15(1):11-5. PubMed ID: 23396236 [TBL] [Abstract][Full Text] [Related]
14. Intralesional application of epidermal growth factor in limb-threatening ischemic diabetic foot ulcers. Aktaş Ş; Baktıroğlu S; Demir L; Kılıçoğlu Ö; Topalan M; Güven E; Mirasoğlu B; Yanar F Acta Orthop Traumatol Turc; 2016; 50(3):277-83. PubMed ID: 27130382 [TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor enhances healing of diabetic foot ulcers. Tsang MW; Wong WK; Hung CS; Lai KM; Tang W; Cheung EY; Kam G; Leung L; Chan CW; Chu CM; Lam EK Diabetes Care; 2003 Jun; 26(6):1856-61. PubMed ID: 12766123 [TBL] [Abstract][Full Text] [Related]
16. The evidence for the use of growth factors and active skin substitutes for the treatment of non-infected diabetic foot ulcers (DFU): a health technology assessment (HTA). Buchberger B; Follmann M; Freyer D; Huppertz H; Ehm A; Wasem J Exp Clin Endocrinol Diabetes; 2011 Sep; 119(8):472-9. PubMed ID: 21811960 [TBL] [Abstract][Full Text] [Related]